Figure 2From: A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season Antimotavizumab and antipalivizumab antibodies detected during the study. Antimotavizumab titers ranged from 1:40 to 1:1250 in the mixed motavizumab/palivizumab treatment group and from 1:10 to 1:250 in the mixed palivizumab/motavizumab treatment group. Final antibody assessments at days 270 to 300 correspond to 120-150 days after the final dose.Back to article page